Studies in the Area of Acyclovir Therapy Reported from Department of Pharmaceuticals [In-vitro release of acyclovir loaded Eudragit RLPO ® nanoparticles for sustained drug delivery]
By a News Reporter-Staff News Editor at Biotech Week -- Investigators discuss new findings in Drugs and Therapies. According to news reporting from Bengal, India, by NewsRx journalists, research stated, "In this present study the possibility to develop Eudragit RLPO ® based nanoparticles of acyclovir was investigated in order to increase its efficacy because acyclovir has oral bioavailability of only 10-20% thus showing erratic absorption and bioavailability behaviour. The nanoparticles were prepared by nanoprecipitation technique."
The news correspondents obtained a quote from the research from the Department of Pharmaceuticals, "Pluronic F68 was used as stabilizer. The nanoparticles were characterized by particle size, entrapment efficiency, DSC, SEM, FTIR and in-vitro drug release. It was found that as drug:polymer (Acyclovir:Eudragit RLPO ®) ratio increased from 1:1.5 to 1:2, particle size was increased significantly and drug entrapment also increased but thereafter, further increase in drug: polymer ratio showed reduced or insignificant change in the drug entrapment efficiency. DSC results showed that in the prepared nanoaprticles, the drug was present in the amorphous phase and may have been homogeneously dispersed in the polymer matrix. In vitro drug release study of formulations showed release in 24 h in the range 71.62 +/- 1.72 to 93.25 +/- 1.02%. The release was found to follow Higuchi model with non-Fickian diffusion mechanism for all batches."
According to the news reporters, the research concluded: "These preliminary results indicate that acyclovir loaded Eudragit RLPO nanoparticles could be effective in sustaining drug release for a prolonged period."
For more information on this research see: In-vitro release of acyclovir loaded Eudragit RLPO ® nanoparticles for sustained drug delivery. International Journal of Biological Macromolecules, 2014;67():478-482. International Journal of Biological Macromolecules can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; International Journal of Biological Macromolecules - www.elsevier.com/wps/product/cws_home/525446)
Our news journalists report that additional information may be obtained by contacting A. Gandhi, Gupta Coll Technol Sci, Dept. of Pharmaceut, Asansol 713301, W Bengal, India. Additional authors for this research include S. Jana and K.K. Sen (see also Drugs and Therapies).
Keywords for this news article include: Asia, Antiinfectives, Pharmaceuticals, India, Bengal, Acyclovir, Nanoparticle, Nanotechnology, Topical Agents, Purine Nucleosides, Topical Antivirals, Drugs and Therapies, Dermatological Agents, Drug Delivery Systems, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC